Q1 EPS Estimates for OTCMKTS:MDNAF Raised by HC Wainwright

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF) – Equities researchers at HC Wainwright lifted their Q1 2027 EPS estimates for Medicenna Therapeutics in a research note issued to investors on Thursday, July 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.04) for the quarter, up from their previous estimate of ($0.05). The consensus estimate for Medicenna Therapeutics’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Medicenna Therapeutics’ Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at ($0.07) EPS.

Medicenna Therapeutics Stock Performance

MDNAF stock opened at $0.26 on Tuesday. Medicenna Therapeutics has a 52 week low of $0.25 and a 52 week high of $1.43. The company has a 50-day moving average of $0.35. The firm has a market capitalization of $24.24 million, a P/E ratio of -1.64 and a beta of 1.75.

Medicenna Therapeutics (OTCMKTS:MDNAF) last issued its quarterly earnings results on Thursday, June 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05).

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.